Name:	imgn_CollaborativeArrangementAllocationOfDeliverablesAssumptionsUtilizationPeriod
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Represents the fair value of the imputed consideration payable under the collaborative agreement for services received.

No definition available.

Name:	imgn_CollaborativeArrangementConsiderationPayableFairValue
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Represents the estimated term of licenses under the collaborative arrangements.

No definition available.

Name:	imgn_CollaborativeArrangementLicensesEstimatedTerm
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Represents the amount of potential payments that could be received under the collaborative agreement.

No definition available.

Name:	imgn_CollaborativeArrangementMilestonePaymentsPotential
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Represents the amount of potential payments that could be paid under the collaborative agreement.

No definition available.

Name:	imgn_CollaborativeArrangementPotentialMilestonePaymentsPayable
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Revenue from multiple-deliverable arrangements that include milestone and licensing fees revenue. Milestone revenue is consideration received upon achieving contractual goals. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets.

No definition available.

Name:	imgn_LicenseAndMilestoneFees
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Name:	us-gaap_DeferredRevenueNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Name:	us-gaap_FairValueInputsDiscountRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

Cash received from collaborators during the current period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Name:	us-gaap_CounterpartyNameAxis=imgn_CytomXTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_FutureTechnologicalImprovementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_ResearchServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=imgn_RightToTestMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=imgn_DevelopmentAndCommercializationLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	imgn_DevelopmentPhaseAxis=imgn_PhaseIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: